Clonal plasma cells in multiple myeloma have been found to be sensitive to inhibition of BCL-2 and MCL-1 at initial diagnosis, with increased MCL-1 dependence in relapsed disease, yet the heterogeneity in these dependencies has hampered treatment progress38–40. This evidence concerns the gene MCL1 and AL amyloidosis.